Literature DB >> 24718809

A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer.

Fatemeh Bahreini1, Ali Reza Soltanian2, Parvin Mehdipour3.   

Abstract

BACKGROUND: We performed this meta-analysis study to evaluate the concordance and discordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in detecting HER2 alteration in human breast cancer.
METHODS: As a meta-analysis, the present study evaluated the available data from previous studies on the HER2 gene detected by IHC and FISH. To indicate the meta-analysis results, a forest plot was used.
RESULTS: We identified 172 citations, for which our inclusion criteria were met by 18 articles, representing 6629 cases. The overall concordance and discordance rate between IHC staining with score 0/1+ and FISH for detection failure of HER2 expression was 96 and 4 %, respectively. The present study showed that the overall proportion of FISH positive and negative rate for IHC score 2+ for detection of HER2 expression was 36 and 64 %, respectively; and 91 and 9 % for 3+ IHC scores.
CONCLUSION: The results of this study show that IHC score 0/1+ and 3+ cannot be completely considered as negative and positive breast cancer test, respectively. Therefore, we suggest a valid and complementary test, the same as FISH, to explore HER2 expression.

Entities:  

Keywords:  Breast cancer; Fluorescence in situ hybridization; HER2; Immunohistochemistry; Meta-analysis

Mesh:

Substances:

Year:  2014        PMID: 24718809     DOI: 10.1007/s12282-014-0528-0

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  20 in total

1.  Digital image analysis outperforms manual biomarker assessment in breast cancer.

Authors:  Gustav Stålhammar; Nelson Fuentes Martinez; Michael Lippert; Nicholas P Tobin; Ida Mølholm; Lorand Kis; Gustaf Rosin; Mattias Rantalainen; Lars Pedersen; Jonas Bergh; Michael Grunkin; Johan Hartman
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

2.  Diagnostic Accuracy of BRAF Immunohistochemistry in Colorectal Cancer: a Meta-Analysis and Diagnostic Test Accuracy Review.

Authors:  Jung-Soo Pyo; Jin Hee Sohn; Guhyun Kang
Journal:  Pathol Oncol Res       Date:  2016-05-19       Impact factor: 3.201

3.  Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer.

Authors:  Willemijne A M E Schrijver; Petra van der Groep; Laurien Dc Hoefnagel; Natalie D Ter Hoeve; Ton Peeters; Cathy B Moelans; Paul J van Diest
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

4.  Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer.

Authors:  Yongling Ji; Liming Sheng; Xianghui Du; Guoqin Qiu; Bo Chen; Xiaojia Wang
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

5.  Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.

Authors:  Gilda Schmidt; Christoph Gerlinger; Ingolf Juhasz-Böss; Elmar Stickeler; Achim Rody; Cornelia Liedtke; Pauline Wimberger; Theresa Link; Eberhard Müller; Tanja Fehm; Manuela Abel; Stefan Stein; Rainer Bohle; Jan Endrikat; Erich-Franz Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-23       Impact factor: 4.553

6.  HER2 expression status in diverse cancers: review of results from 37,992 patients.

Authors:  Min Yan; Maria Schwaederle; David Arguello; Sherri Z Millis; Zoran Gatalica; Razelle Kurzrock
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

7.  The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.

Authors:  Hui Luo; Xiaohui Xu; Miaomiao Ye; Bo Sheng; Xueqiong Zhu
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

8.  CD74 and intratumoral immune response in breast cancer.

Authors:  Zhi-Qiang Wang; Katy Milne; John R Webb; Peter H Watson
Journal:  Oncotarget       Date:  2017-02-21

9.  Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?

Authors:  Mehrdad Payandeh; Masoud Sadeghi; Edris Sadeghi; Alireza Janbakhsh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-01-01

10.  High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence.

Authors:  Brad E Wasserman; Daniel E Carvajal-Hausdorf; Kenneth Ho; Wendy Wong; Natalie Wu; Victor C Chu; Edwin W Lai; Jodi M Weidler; Michael Bates; Veronique Neumeister; David L Rimm
Journal:  Lab Invest       Date:  2017-09-11       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.